234 related articles for article (PubMed ID: 29631195)
1. Vaccine options for influenza: thinking small.
Schepens B; De Vlieger D; Saelens X
Curr Opin Immunol; 2018 Aug; 53():22-29. PubMed ID: 29631195
[TBL] [Abstract][Full Text] [Related]
2. Protection against multiple influenza A virus strains induced by candidate recombinant vaccine based on heterologous M2e peptides linked to flagellin.
Stepanova LA; Kotlyarov RY; Kovaleva AA; Potapchuk MV; Korotkov AV; Sergeeva MV; Kasianenko MA; Kuprianov VV; Ravin NV; Tsybalova LM; Skryabin KG; Kiselev OI
PLoS One; 2015; 10(3):e0119520. PubMed ID: 25799221
[TBL] [Abstract][Full Text] [Related]
3. Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection.
El Bakkouri K; Descamps F; De Filette M; Smet A; Festjens E; Birkett A; Van Rooijen N; Verbeek S; Fiers W; Saelens X
J Immunol; 2011 Jan; 186(2):1022-31. PubMed ID: 21169548
[TBL] [Abstract][Full Text] [Related]
4. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin.
Huleatt JW; Nakaar V; Desai P; Huang Y; Hewitt D; Jacobs A; Tang J; McDonald W; Song L; Evans RK; Umlauf S; Tussey L; Powell TJ
Vaccine; 2008 Jan; 26(2):201-14. PubMed ID: 18063235
[TBL] [Abstract][Full Text] [Related]
5. Complement C3 Plays a Key Role in Inducing Humoral and Cellular Immune Responses to Influenza Virus Strain-Specific Hemagglutinin-Based or Cross-Protective M2 Extracellular Domain-Based Vaccination.
Kim YJ; Kim KH; Ko EJ; Kim MC; Lee YN; Jung YJ; Lee YT; Kwon YM; Song JM; Kang SM
J Virol; 2018 Oct; 92(20):. PubMed ID: 30068650
[TBL] [Abstract][Full Text] [Related]
6. Passively transferred M2e-specific monoclonal antibody reduces influenza A virus transmission in mice.
Kolpe A; Schepens B; Ye L; Staeheli P; Saelens X
Antiviral Res; 2018 Oct; 158():244-254. PubMed ID: 30179634
[TBL] [Abstract][Full Text] [Related]
7. Complete protection against a H5N2 avian influenza virus by a DNA vaccine expressing a fusion protein of H1N1 HA and M2e.
Park KS; Seo YB; Lee JY; Im SJ; Seo SH; Song MS; Choi YK; Sung YC
Vaccine; 2011 Jul; 29(33):5481-7. PubMed ID: 21664216
[TBL] [Abstract][Full Text] [Related]
8. Hierarchical and Redundant Roles of Activating FcγRs in Protection against Influenza Disease by M2e-Specific IgG1 and IgG2a Antibodies.
Van den Hoecke S; Ehrhardt K; Kolpe A; El Bakkouri K; Deng L; Grootaert H; Schoonooghe S; Smet A; Bentahir M; Roose K; Schotsaert M; Schepens B; Callewaert N; Nimmerjahn F; Staeheli P; Hengel H; Saelens X
J Virol; 2017 Apr; 91(7):. PubMed ID: 28077656
[TBL] [Abstract][Full Text] [Related]
9. Increased immunogenicity and protective efficacy of influenza M2e fused to a tetramerizing protein.
Andersson AM; Håkansson KO; Jensen BA; Christensen D; Andersen P; Thomsen AR; Christensen JP
PLoS One; 2012; 7(10):e46395. PubMed ID: 23049700
[TBL] [Abstract][Full Text] [Related]
10. Chimeric Hemagglutinin Constructs Induce Broad Protection against Influenza B Virus Challenge in the Mouse Model.
Ermler ME; Kirkpatrick E; Sun W; Hai R; Amanat F; Chromikova V; Palese P; Krammer F
J Virol; 2017 Jun; 91(12):. PubMed ID: 28356526
[TBL] [Abstract][Full Text] [Related]
11. The Role of Matrix Protein 2 Ectodomain in the Development of Universal Influenza Vaccines.
Saelens X
J Infect Dis; 2019 Apr; 219(Suppl_1):S68-S74. PubMed ID: 30715367
[TBL] [Abstract][Full Text] [Related]
12. Combination of M2e peptide with stalk HA epitopes of influenza A virus enhances protective properties of recombinant vaccine.
Tsybalova LM; Stepanova LA; Shuklina MA; Mardanova ES; Kotlyarov RY; Potapchuk MV; Petrov SA; Blokhina EA; Ravin NV
PLoS One; 2018; 13(8):e0201429. PubMed ID: 30138320
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and efficacy of replication-competent recombinant influenza virus carrying multimeric M2 extracellular domains in a chimeric hemagglutinin conjugate.
Kim MC; Lee YN; Kim YJ; Choi HJ; Kim KH; Lee YJ; Kang SM
Antiviral Res; 2017 Dec; 148():43-52. PubMed ID: 29107058
[TBL] [Abstract][Full Text] [Related]
14. Universal influenza A M2e-HBc vaccine protects against disease even in the presence of pre-existing anti-HBc antibodies.
De Filette M; Martens W; Smet A; Schotsaert M; Birkett A; Londoño-Arcila P; Fiers W; Saelens X
Vaccine; 2008 Dec; 26(51):6503-7. PubMed ID: 18835315
[TBL] [Abstract][Full Text] [Related]
15. Porous Nanoparticles With Self-Adjuvanting M2e-Fusion Protein and Recombinant Hemagglutinin Provide Strong and Broadly Protective Immunity Against Influenza Virus Infections.
Bernasconi V; Bernocchi B; Ye L; Lê MQ; Omokanye A; Carpentier R; Schön K; Saelens X; Staeheli P; Betbeder D; Lycke N
Front Immunol; 2018; 9():2060. PubMed ID: 30271406
[TBL] [Abstract][Full Text] [Related]
16. An influenza A virus vaccine based on an M2e-modified alphavirus.
Krishnavajhala HR; Williams J; Heidner H
Arch Virol; 2018 Feb; 163(2):483-488. PubMed ID: 29079954
[TBL] [Abstract][Full Text] [Related]
17. Recombinant M2e outer membrane vesicle vaccines protect against lethal influenza A challenge in BALB/c mice.
Rappazzo CG; Watkins HC; Guarino CM; Chau A; Lopez JL; DeLisa MP; Leifer CA; Whittaker GR; Putnam D
Vaccine; 2016 Mar; 34(10):1252-8. PubMed ID: 26827663
[TBL] [Abstract][Full Text] [Related]
18. Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity.
Jegerlehner A; Schmitz N; Storni T; Bachmann MF
J Immunol; 2004 May; 172(9):5598-605. PubMed ID: 15100303
[TBL] [Abstract][Full Text] [Related]
19. In contrast to conventional inactivated influenza vaccines, 4xM2e.HSP70c fusion protein fully protected mice against lethal dose of H1, H3 and H9 influenza A isolates circulating in Iran.
Ebrahimi SM; Dabaghian M; Tebianian M; Jazi MH
Virology; 2012 Aug; 430(1):63-72. PubMed ID: 22595444
[TBL] [Abstract][Full Text] [Related]
20. Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2e peptide into the immunodominant region of hepatitis B core antigen: Broad protective efficacy of particles carrying four copies of M2e.
Tsybalova LM; Stepanova LA; Kuprianov VV; Blokhina EA; Potapchuk MV; Korotkov AV; Gorshkov AN; Kasyanenko MA; Ravin NV; Kiselev OI
Vaccine; 2015 Jun; 33(29):3398-406. PubMed ID: 25976545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
